# Eating Too Little on a GLP-1: What the Deficiency Data Show

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-19 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/eating-too-little-on-a-glp1

> Across 480,825 adults, more than 60% took in less calcium and iron than their estimated requirements, vitamin D deficiency reached 13.6% at a year, and ferritin ran 26–30% below an active comparator.

## Key points

- More than 60% of users ate below estimated requirements for calcium and iron.
- Vitamin D deficiency 7.5% at six months, 13.6% at twelve; ferritin 26–30% below a comparator.
- Wernicke encephalopathy: 19 cases and a VigiBase signal; 68% involved vomiting or low intake.
- Eat to a target rather than to appetite, because appetite is the instrument the drug switched off.

The drug is supposed to make you eat less, and it does: three weeks into one tirzepatide trial, people ate [about 525 fewer calories at a single lunch](https://glpwatchdog.org/research/five-hundred-calories-at-one-lunch) than those on placebo. The problem is that the drug does not distinguish between eating less and eating badly, and the evidence suggests most people end up doing both. Across six studies covering **480,825 adults**, calcium and iron intake fell below estimated requirements in more than **60%** of GLP-1 users, vitamin D deficiency reached 13.6% by twelve months, and ferritin ran 26–30% below an active comparator.[1]

## Why appetite suppression does this

Three mechanisms stack, and the review names all three: appetite suppression, delayed gastric emptying, and altered absorption.[1] Eating less means less of everything. The body does not preferentially discard the calories you did not need.

There is a second, subtler problem. When appetite is low, the foods people keep are usually the easy ones. Protein-dense and fiber-dense foods feel heaviest and get dropped first, which is exactly backwards for anyone trying to protect muscle and bowel function while losing weight. [Snacks compared by protein per calorie](https://glpwatchdog.org/research/low-calorie-snacks-on-a-glp1) shows which small foods close that gap.

## What is actually running low

*Nutritional findings from a 2026 review of six studies, 480,825 adults on GLP-1 therapy.*

| Finding | Detail |
| --- | --- |
| Calcium and iron intake below estimated requirements | **More than 60%** of users |
| Vitamin D deficiency | 7.5% at six months, rising to 13.6% at twelve |
| Iron status | Ferritin 26–30% lower than SGLT2 inhibitor comparators |

The iron figure matters because of its comparison group. These users were measured against people taking a different drug for the same conditions, not against the healthy general population, and that strips out a lot of confounding. A 26–30% gap in that comparison is harder to explain away, though the review notes its findings are mainly observational and cannot establish that the drug caused them.[1]

Low iron and low vitamin D both produce fatigue, which is one reason our [fatigue article](https://glpwatchdog.org/research/glp1-fatigue-what-causes-it) lists them as the first things to check before assuming the drug is doing it directly.

## The rare end, and why it is here

Wernicke encephalopathy is acute brain injury caused by thiamine deficiency. It presents with confusion, abnormal eye movements and unsteadiness, it is a medical emergency, and it is largely reversible if treated quickly but not if treatment is delayed.

A 2025 analysis gathered a case in a 49-year-old woman on semaglutide alongside eighteen others from the literature and the World Health Organization’s VigiBase, and ran a disproportionality analysis. Wernicke encephalopathy was disproportionately reported with semaglutide, with tirzepatide, and with the GLP-1 class as a whole. In **68%** of cases there was vomiting or reduced food intake, with weight loss running from 3.5 to 13.3 kg per month.[2]

> In 68% of the nineteen reported cases, there was vomiting or reduced food intake.

Nineteen cases against many millions of prescriptions makes this rare. It is included here because thiamine deficiency is cheap to prevent, because the risk factors are the ordinary side effects of the drug and nothing exotic, and because the authors describe their own finding as a safety signal requiring prompt assessment.[2]

> **Confusion, double vision or trouble walking in someone who has been vomiting or barely eating is an emergency.** That combination is how Wernicke encephalopathy presents, it is treated with thiamine, and delay is what turns it permanent. Say what you have been taking and how little you have eaten. Milder, gradual fog has more ordinary causes, set out in [brain fog on a GLP-1](https://glpwatchdog.org/research/glp1-brain-fog).

## How much weight loss is too fast

The Wernicke cases ran between 3.5 and 13.3 kg a month.[2] For context, the pivotal trials averaged roughly 15% of body weight over 68 weeks, a far slower rate. Losing weight much faster than the trials did usually reflects intake low enough to matter, not a drug working better.

Rapid loss also drives other risks: [gallstones](https://glpwatchdog.org/research/glp1-pancreatitis-and-gallbladder-risk), where the label notes the excess persisted even after adjusting for how much weight came off, and loss of [lean mass](https://glpwatchdog.org/research/glp1-hair-loss-and-muscle-loss).

## What to do about it

- **Eat to a target, not to appetite.** Appetite is the thing the drug has switched off, which makes it a broken instrument for deciding how much to eat. Our [protein](https://glpwatchdog.org/tools/glp1-protein-calculator) and [fiber](https://glpwatchdog.org/tools/glp1-fiber-calculator) calculators give numbers to aim at.
- **Ask for blood work instead of assuming.** Vitamin D, ferritin and B12 are cheap, routine, and the ones this evidence points at.
- **Treat persistent vomiting as urgent rather than expected.** It is the common thread in the severe cases, and it also drives the dehydration behind the [acute kidney injury](https://glpwatchdog.org/research/glp1-and-your-kidneys) the label warns about.
- **Do not assume a supplement covers it.** A multivitamin is reasonable, but no trial has shown which regimen prevents these specific deficiencies on these specific drugs, and a prescriber who measures beats a guess.

## Frequently asked questions

### Is it possible to eat too little on a GLP-1?

Yes, and for some nutrients most users do. A 2026 review of six studies covering 480,825 adults found calcium and iron intake below estimated requirements in more than 60% of users, with vitamin D deficiency reaching 13.6% at twelve months and ferritin 26–30% below an active comparator.

### Which nutrients run low?

Vitamin D most commonly, and iron notably. The ferritin gap is measured against people taking a different drug for the same conditions, which makes it harder to explain away. Both produce fatigue, which is why they should be checked before assuming the drug is causing tiredness directly.

### What is Wernicke encephalopathy and should I worry?

It is acute brain injury from thiamine deficiency, presenting with confusion, abnormal eye movements and unsteadiness. Nineteen cases have been reported alongside a disproportionality signal for semaglutide, tirzepatide and the class, with 68% occurring against vomiting or reduced intake. It is rare against many millions of prescriptions. It is worth knowing about because it is preventable and treatable.

### How fast is too fast to lose weight?

The Wernicke cases ran 3.5 to 13.3 kg a month, against roughly 15% of body weight over 68 weeks in the pivotal trials. Losing much faster than the trials produced is not a sign the drug is working better; it usually means intake low enough to matter.

### Should I just take a multivitamin?

It is reasonable, but it is no substitute for measuring. No trial has established which supplementation regimen prevents these specific deficiencies on these specific drugs, and vitamin D, ferritin and B12 are cheap routine tests.

## References

1. Urbina J, Salinas-Ruiz LE, Valenciano C, et al. Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review. Clinical Obesity. 2026. PMID: 41549912. https://pubmed.ncbi.nlm.nih.gov/41549912/
2. Gras C, De Wit V, Oussedik N, et al. Semaglutide-induced Wernicke encephalopathy: a comprehensive analysis. European Journal of Clinical Nutrition. 2025. PMID: 40908328. https://pubmed.ncbi.nlm.nih.gov/40908328/

---

Cite as: GLP Watchdog, Ruth Calder, "Eating Too Little on a GLP-1: What the Deficiency Data Show", published 2026-08-19, updated 2026-10-30. https://glpwatchdog.org/research/eating-too-little-on-a-glp1

Canonical HTML page: https://glpwatchdog.org/research/eating-too-little-on-a-glp1

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
